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OBJECTIVES: To compare clinical outcomes of type 2 diabetic patients with and
without TZDs therapy after patients receiving DES. METHODS: We conducted a
retrospective cohort study using the National Health Insurance Database (NHIRD).
The type 2 diabetes mellitus patients were included if they received first limus-
eluting stent or paclitaxel-eluting stent placement andwere identified by presence
of a hospital claim during the period fromDecember 1, 2006, through December 31,
2007. Follow-up data were available through December 31, 2008. Patients were
classified into two groups based on the antidiabetic agents they took from phar-
macy records for use of TZD (rosiglitazone, pioglitazone) or non-TZD within 3
months after the index date of hospitalization. A total of 1,743 patients who re-
ceived stents during the study period were identified as the study subjects. Our
measure of effectiveness was the prevalence of death, myocardial infarction and
repeat revascularization, defined as any PCI, whether or not the patient received a
stent, or crossed over to CABG within one year after index hospitalization.
RESULTS: There were 268 patients in TZD group, 1,475 patients in non-TZD group.
Compared with non-TZD group, there were no significant difference in adjusted
hazard ratio of death, myocardial infarction and repeat revascularization between
limus-eluting stent group and paclitaxel-eluting stent group. In stratified analysis,
patients who received limus-eluting stent with history of myocardial infarction
and treated with TZDs were associated with a higher risk of myocardial infarction
(HR 5.292, 95% CI1.028– 27.232). CONCLUSIONS:Our findings suggest that TZDs
could not improve clinical outcomes in type 2 diabetes patients after drug-eluting
stent implantation. TZDs may contribute to higher risk of myocardial infarction in
patientwith limus-eluting stent and history ofmyocardial infarction. For the pleio-
tropic effects of TZDs, balance between benefit and risk for cardiovascular events
to different subgroups, may be different.Further studies are required to investigate
this relationship.
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OBJECTIVES: Anemia is a prevalent public health problem associated with in-
creased risk of morbidity and mortality. It is also associated with cardiovascular
disorders (CVDs) including heart failure (HF). In a large community study, 58% ofHF
patients had anemia. There is a wide variation in the reported prevalence of ane-
mia among HF patients (7%-50%). This community based study investigated
whether anemia is associated with HF using data from National Health and Nutri-
tion Examination Survey (NHANES) which is a national survey to assess the health
and nutritional status in the United States. METHODS: NHANES data from the
2005-2006 administration were combined and analyzed cross-sectionally. Descrip-
tive statistics and univariate comparisons were used as appropriate. Weighted
multivariable logistic regression was used to predict and compute odds ratios (OR)
and 95% confidence intervals (CI) of the association between HF and anemia
prevalence. RESULTS: There were 953 respondents with anemia, and 180 respon-
dents had HF. Among those with anemia, the proportion of African Americans was
significantly higher than Caucasians (46% vs. 31%; p0.001; respectively). Respon-
dentswith anemiawere significantlymore likely to have cancer, other CVDs status,
and be pregnant than those without anemia (p0.001, p0.001, and p0.002, re-
spectively). In addition, prevalence of anemia was significantly higher in respon-
dents with HF as compared to those with other CVDs (18% vs. 4%; p0.001). Ap-
proximately 10% of HF respondents had anemia compared to just 2% among those
without HF (OR5.09, CI 5.08-5.11). This association remained statistically signif-
icant after adjusting for age, race, pregnancy status, cancer, smoking status, and
other CVDs (OR5.8, CI 5.54-5.96). CONCLUSIONS: According to this study, the
prevalence of anemia among HF patients is relatively high. African Americans and
those with HF are more likely to experience anemia. The association between HF
and anemia remained after controlling for confounders.
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OBJECTIVES: Current prevalence of cardiovascular risk factors are lacking among
Chinese adults. This study contributes to our knowledge by examining current
national estimates for hypertension, high cholesterol, diabetes and obesity among
Chinese and white adults aged 20 years and older, by gender and age group.
METHODS: Cross-sectional observational study design. Analysis of adults 20 years
and older surveyed in the National Health Interview Surveys 2006-2008 (Chinese, n
 853, white, n 51,769). RESULTS: Among US Chinese adults (2.2 million), hyper-
tension and high cholesterol are equally prevalent (19%, age-standardized), but
significantly lower than the 27% age-standardized prevalence of each condition
among the population of US white adults (176 million). Among Chinese and white
adults aged 65 years and older, hypertension rates are similar, 56% and 59%, re-
spectively, but high cholesterol prevalence is significantly lower among Chinese
adults, 33% vs. 49%, respectively, driven by the lower rate of high cholesterol
among older Chinesemen (27%) than older Chinese women (40%). Overall diabetes
prevalence is significantly lower among Chinese than among white adults (5% vs.
7%), but rates among older adults are similar, 16% and 17%, respectively. Obesity
rates for Chinese adults aged 20-39, 40-64, and 65 are 6%, 8%, and 7%, respectively.
Obesity rates for white adults aged 20-39, 40-64, and 65 are 26%, 34%, and 27%,
respectively (p  0.0001 for all obesity differences). CONCLUSIONS: Overall age-
standardized prevalence rates of hypertension, high cholesterol and diabetes are
lower among Chinese adults. However, among older adults, hypertension and diabe-
tes rates are similar in the Chinese and white populations. Obesity rates are lower
among Chinese adults of all age groups. Effective approaches are recommended to
reduce selected cardiovascular risk factors among both groups of older adults.
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OBJECTIVES: Anticoagulation is recommended for atrial fibrillation (AF) patients
withmoderate-high stroke risk and low risk of bleeding. Previous data have shown
that bleeding rates increase in parallel with stroke risk because stroke and bleeding
risk factors overlap. The objective of this study was to assess whether adding
ATRIA specific bleeding risk variables to the CHADS2 stroke risk variables will
improve the ability to predict major bleeds. METHODS: Medical claims for AF pa-
tients (ICD-9 code 427.31) with continuous eligibility 12 months prior to an AF
diagnosis in the MarketScan database between January 2003 to December 2007
were analyzed. Data before an index AF diagnosis were used to assess the presence
of CHADS2 (congestive heart failure, hypertension, age 75, diabetes, prior stroke/
transient ischemic attack) and ATRIA (anemia, renal disease, age 75, prior bleed-
ing, hypertension) risk factors. The Pearson correlation coefficient between the
CHADS2 and ATRIA risk scores and Cox proportional hazards regressions compar-
ing a reduced model (CHADS2 covariates only) and a full model (CHADS2  ATRIA
covariates) to predict major bleeds after an AF diagnosis were estimated. Likeli-
hood ratio tests were used to test for differences between the models. RESULTS: A
total of 64,946 AF patients were included in the analysis (47%75 years of age, 45%
females). ATRIA and CHADS2 scores were correlated (r0.63, p0.0001). CHADS2
risk factors predicted major bleeding (LR444.66, P0.001). The addition of ATRIA
risk factors enhanced predictive power (LR519.65, P0.001) and resulted in a sig-
nificant improvement in model fit (P0.001). A range of sensitivity analyses re-
vealed similar findings. CONCLUSIONS: Adding ATRIA bleeding risk factors to the
CHADS2 significantly improved the model fit. These results suggest that informa-
tion provided by the ATRIA bleeding risk index improves bleeding risk assessment
and may potentially help optimize anticoagulation decisions. Further research is
needed to assess improvements in model discrimination.
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OBJECTIVES: Passive smoking is accountable each year for approximately 53,000
and 22,000 deaths in the United States and Europe. The aim of this study was to
conduct a meta-analysis of cohort and case-control studies to determine risk fac-
tors to show cardiovascular events and stroke in passive smokers. METHODS: A
systematic review was conducted in February 2010 through Medline, EMBASE, and
the Cochrane Collaboration. Selection criteria variables were: case-control, cohort
and cross-sectional studieswere all studiesmust include exposed and not exposed
subjects to environmental tobacco smoke. Two independent reviewers identified
the abstracts, selected the full articles, and extracted the data. Odds ratios (OR) and
weighted means differences were calculated. Random effects models were em-
ployed in the analyses with each of the estimated variables with Meta-Analysis v.2
software. RESULTS: A total of 821 studies were reviewed and 39 trials were finally
selected. 18/39 studieswere case-control studies, 16/39 studieswere cohort studies
and 5/39 were cross-sectional studies; 29/39 assessed cardiovascular events and
18/39 studies assessed stroke events. Three different tobacco smoke exposure
measurements were defined:1) 17/39 studies were related to spouse smoking hab-
its; 2) 18/39 were according to home and closed spaces behavior exposures; and 3)
4/39 were clinical measurements (serum levels of nicotine or nicotine metabolite).
Relative Risk (RR) to develop a cardiovascular event for passive smokers in case-
control studies (1.466; CI95% 1.301-1.651, p0.001) was higher in comparison to
cross-sectional studies (OR 1.264; 1.203-1.327, p0.001). RR to develop stroke events
was also higher for cohort studies (RR 1.253; 1.038-1.513, p0.019) compared to
case-control studies (OR 1.442; 1.280-1.625, p0.001). No meaningful differences
were found between male/female populations. CONCLUSIONS: Passive smoking
increases the risk to develop a cardiovascular event or stroke by approximately
30%. Health care policymakers should consider these results to implement policies
that enhance exposure reduction of environmental tobacco smoke.
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